AstraZeneca Pharma shares surge over 4% after approval for cancer treatment

On March 27, shares of AstraZeneca Pharma India increased over 4 percent after its announcement that it had received permission from the Central Drugs Standard Control Organisation to import, sell, and distribute Trastuzumab deruxtecan lyophilized powder concentrate for solution for infusion 100mg Enhertu.

Trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-Low breast cancer and locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma, who have received prior chemotherapy or trastuzumab-based regimen respectively.


AstraZeneca Pharma expressed optimism about the launch of Trastuzumab deruxtecan in India, pending statutory approvals. As of 12:12 pm, the shares were trading 3.49% higher at ₹5,260.00 on NSE.